{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:05:15Z","timestamp":1740146715009,"version":"3.37.3"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272200700016I"],"award-info":[{"award-number":["HHSN272200700016I"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272200700016I"],"award-info":[{"award-number":["HHSN272200700016I"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272200700016I"],"award-info":[{"award-number":["HHSN272200700016I"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800013C"],"award-info":[{"award-number":["HHSN272201800013C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Ebola virus (EBOV), a member of the mononegaviral family <jats:italic>Filoviridae<\/jats:italic>, causes severe disease associated with high lethality in humans. Despite enormous progress in development of EBOV medical countermeasures, no anti-EBOV treatment has been approved. We designed an immunotoxin in which a single-chain variable region fragment of the EBOV glycoprotein-specific monoclonal antibody 6D8 was fused to the effector domains of <jats:italic>Pseudomonas aeruginosa<\/jats:italic> exotoxin A (PE38). This immunotoxin, 6D8-PE38, bound specifically to cells expressing EBOV glycoproteins. Importantly, 6D8-PE38 targeted EBOV-infected cells, as evidenced by inhibition of infectious EBOV production from infected cells, including primary human macrophages. The data presented here provide a proof of concept for immunotoxin-based targeted killing of infected cells as a potential antiviral intervention for Ebola virus disease.<\/jats:p>","DOI":"10.1371\/journal.pone.0245024","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T23:20:58Z","timestamp":1610061658000},"page":"e0245024","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1101-0920","authenticated-orcid":true,"given":"Yingyun","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuiqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheli R.","family":"Radoshitzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-6045","authenticated-orcid":true,"given":"Jens H.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8457-3997","authenticated-orcid":true,"given":"Edward A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"1","key":"pone.0245024.ref001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease.","volume":"6","author":"ST Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"pone.0245024.ref002","unstructured":"World Health Organization. Ebola outbreak 2014\u20132015. http:\/\/www.who.int\/csr\/disease\/ebola\/en\/. 2017."},{"key":"pone.0245024.ref003","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-76565-5","volume-title":"A day-by-day chronicle of the 2013\u20132016 Ebola outbreak","author":"SG Bullard","year":"2018"},{"key":"pone.0245024.ref004","unstructured":"World Health Organization. Ebola in the Democratic Republic of the Congo, North Kivu, Ituri 2018\u20132020. https:\/\/www.who.int\/emergencies\/diseases\/ebola\/drc-2019. 2020."},{"key":"pone.0245024.ref005","unstructured":"Food and Drug Administration. First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response. https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health. 2019."},{"key":"pone.0245024.ref006","first-page":"449","volume-title":"Filoviridae","author":"JH Kuhn","year":"2020","edition":"7"},{"issue":"24","key":"pone.0245024.ref007","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"S Mulangu","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0245024.ref008","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1128\/JVI.76.12.6408-6412.2002","article-title":"Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody","volume":"76","author":"PWHI Parren","year":"2002","journal-title":"J Virol"},{"issue":"7","key":"pone.0245024.ref009","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"T Maruyama","year":"1999","journal-title":"J Virol"},{"issue":"1","key":"pone.0245024.ref010","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1371\/journal.ppat.0030009","article-title":"Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.","volume":"3","author":"WB Oswald","year":"2007","journal-title":"PLoS Pathog."},{"issue":"199","key":"pone.0245024.ref011","doi-asserted-by":"crossref","first-page":"199ra13","DOI":"10.1126\/scitranslmed.3006608","article-title":"Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.","volume":"5","author":"J Pettitt","year":"2013","journal-title":"Sci Transl Med."},{"issue":"4","key":"pone.0245024.ref012","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection","volume":"174","author":"EO Saphire","year":"2018","journal-title":"Cell"},{"key":"pone.0245024.ref013","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.3389\/fmicb.2019.02340","article-title":"Targeted diphtheria toxin-based therapy: a review article.","volume":"10","author":"F Shafiee","year":"2019","journal-title":"Front Microbiol."},{"issue":"9","key":"pone.0245024.ref014","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/17474086.2019.1643231","article-title":"Moxetumomab pasudotox for the treatment of relapsed and\/or refractory hairy cell leukemia","volume":"12","author":"I Abou Dalle","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"pone.0245024.ref015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/biomedicines4020012","article-title":"Plant toxin-based immunotoxins for cancer therapy: a short overview","volume":"4","author":"L Polito","year":"2016","journal-title":"Biomedicines"},{"issue":"23","key":"pone.0245024.ref016","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1111\/j.1742-4658.2011.08182.x","article-title":"A guide to taming a toxin\u2014recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer","volume":"278","author":"JE Weldon","year":"2011","journal-title":"FEBS J"},{"issue":"5","key":"pone.0245024.ref017","doi-asserted-by":"crossref","first-page":"e0004709","DOI":"10.1371\/journal.pntd.0004709","article-title":"Characterization of yellow fever virus infection of human and non-human primate antigen presenting cells and their interaction with CD4+ T cells.","volume":"10","author":"Y Cong","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"Suppl 5","key":"pone.0245024.ref018","doi-asserted-by":"crossref","first-page":"S672","DOI":"10.1093\/infdis\/jiy304","article-title":"Identification of combinations of approved drugs with synergistic activity against Ebola virus in cell cultures","volume":"218","author":"J Dyall","year":"2018","journal-title":"J Infect Dis"},{"issue":"3","key":"pone.0245024.ref019","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.antiviral.2011.03.175","article-title":"An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection","volume":"90","author":"Y Cai","year":"2011","journal-title":"Antiviral Res"},{"issue":"2","key":"pone.0245024.ref020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/mabs.4.2.19262","article-title":"Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.","volume":"4","author":"D Chatterjee","year":"2012","journal-title":"MAbs"},{"issue":"16","key":"pone.0245024.ref021","doi-asserted-by":"crossref","first-page":"10442","DOI":"10.1128\/JVI.79.16.10442-10450.2005","article-title":"Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function","volume":"79","author":"VM Wahl-Jensen","year":"2005","journal-title":"J Virol"},{"issue":"1","key":"pone.0245024.ref022","doi-asserted-by":"crossref","first-page":"e1001258","DOI":"10.1371\/journal.ppat.1001258","article-title":"Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus.","volume":"7","author":"IC Huang","year":"2011","journal-title":"PLoS Pathog."},{"issue":"5458","key":"pone.0245024.ref023","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus","volume":"287","author":"JA Wilson","year":"2000","journal-title":"Science"},{"key":"pone.0245024.ref024","first-page":"503","volume-title":"Recombinant immunotoxins in the treatment of cancer","author":"R Pastan","year":"2003"},{"issue":"15","key":"pone.0245024.ref025","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","article-title":"Emergence of Zaire Ebola virus disease in Guinea","volume":"371","author":"S Baize","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0245024.ref026","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.3390\/v6114760","article-title":"Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014.","volume":"6","author":"JH Kuhn","year":"2014","journal-title":"Viruses"},{"key":"pone.0245024.ref027","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1749-6632.1990.tb17835.x","article-title":"Anti-HIV effects of CD4- Pseudomonas exotoxin on human lymphocyte and monocyte\/macrophage cell lines","volume":"616","author":"P Ashorn","year":"1990","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"pone.0245024.ref028","first-page":"1476","article-title":"Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.","volume":"6","author":"RJ Kreitman","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"Suppl 5","key":"pone.0245024.ref029","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1093\/infdis\/jiy334","article-title":"The past need not be prologue: recommendations for testing and positioning the most-promising medical countermeasures for the next outbreak of Ebola virus infection","volume":"218","author":"RT Davey","year":"2018","journal-title":"J Infect Dis"},{"issue":"10","key":"pone.0245024.ref030","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41579-019-0233-2","article-title":"Therapeutic strategies to target the Ebola virus life cycle","volume":"17","author":"T Hoenen","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"pone.0245024.ref031","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coviro.2016.01.006","article-title":"Antibody therapeutics for Ebola virus disease.","volume":"17","author":"L Zeitlin","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"11","key":"pone.0245024.ref032","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"EO Saphire","year":"2018","journal-title":"Nat Immunol"},{"issue":"8","key":"pone.0245024.ref033","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S1473-3099(18)30397-9","article-title":"Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study","volume":"18","author":"S Sivapalasingam","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10174","key":"pone.0245024.ref034","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.","volume":"393","author":"MR Gaudinski","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"pone.0245024.ref035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbmt.2017.10.004","article-title":"Virus-specific T cells: broadening applicability","volume":"24","author":"AJ Barrett","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1680","key":"pone.0245024.ref036","doi-asserted-by":"crossref","first-page":"20140374","DOI":"10.1098\/rstb.2014.0374","article-title":"T cell engineering as therapy for cancer and HIV: our synthetic future","volume":"370","author":"CH June","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"2","key":"pone.0245024.ref037","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11904-018-0388-x","article-title":"Quarter century of anti-HIV CAR T cells","volume":"15","author":"TA Wagner","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"pone.0245024.ref038","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymeth.2018.10.010","article-title":"Bispecific antibodies: potential immunotherapies for HIV treatment.","volume":"154","author":"G Fabozzi","year":"2019","journal-title":"Methods."},{"issue":"2","key":"pone.0245024.ref039","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.2014-0358","article-title":"Advances in anticancer immunotoxin therapy.","volume":"20","author":"C Alewine","year":"2015","journal-title":"Oncologist"},{"issue":"1","key":"pone.0245024.ref040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.xphs.2019.10.037","article-title":"Critical issues in the development of immunotoxins for anticancer therapy","volume":"109","author":"J-S Kim","year":"2020","journal-title":"J Pharm Sci"},{"key":"pone.0245024.ref041","first-page":"403","volume-title":"Anti-HIV immunotoxins.","author":"SH Pincus","year":"2003"},{"issue":"6","key":"pone.0245024.ref042","doi-asserted-by":"crossref","first-page":"e1000803","DOI":"10.1371\/journal.ppat.1000803","article-title":"Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs","volume":"6","author":"EA Berger","year":"2010","journal-title":"PLoS Pathog"},{"issue":"6","key":"pone.0245024.ref043","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1189\/jlb.2MR1015-468R","article-title":"The future of antiviral immunotoxins","volume":"99","author":"K Spiess","year":"2016","journal-title":"J Leukoc Biol"},{"key":"pone.0245024.ref044","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.coi.2018.05.001","article-title":"The structural basis for filovirus neutralization by monoclonal antibodies","volume":"53","author":"LB King","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"Suppl 5","key":"pone.0245024.ref045","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/infdis\/jiy285","article-title":"Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates","volume":"218","author":"KE Pascal","year":"2018","journal-title":"J Infect Dis"},{"issue":"8","key":"pone.0245024.ref046","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"RJ Kreitman","year":"2018","journal-title":"Leukemia"},{"issue":"7520","key":"pone.0245024.ref047","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"X Qiu","year":"2014","journal-title":"Nature"},{"issue":"8","key":"pone.0245024.ref048","doi-asserted-by":"crossref","first-page":"e1002847","DOI":"10.1371\/journal.ppat.1002847","article-title":"The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo","volume":"8","author":"A Groseth","year":"2012","journal-title":"PLoS Pathog"},{"issue":"1","key":"pone.0245024.ref049","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/viro.2000.0601","article-title":"Downregulation of \u03b21 integrins by Ebola virus glycoprotein: implication for virus entry","volume":"278","author":"A Takada","year":"2000","journal-title":"Virology"},{"issue":"5","key":"pone.0245024.ref050","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/jvi.76.5.2518-2528.2002","article-title":"Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence","volume":"76","author":"G Simmons","year":"2002","journal-title":"J Virol"},{"issue":"22","key":"pone.0245024.ref051","doi-asserted-by":"crossref","first-page":"8889","DOI":"10.1073\/pnas.87.22.8889","article-title":"Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors","volume":"87","author":"P Ashorn","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0245024.ref052","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coviro.2017.02.006","article-title":"Ebola virus persistence as a new focus in clinical research","volume":"23","author":"K Caviness","year":"2017","journal-title":"Curr Opin Virol"},{"issue":"9","key":"pone.0245024.ref053","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1473-3099(20)30282-6","article-title":"Recent successes in therapeutics for Ebola virus disease: no time for complacency","volume":"20","author":"PL Iversen","journal-title":"Lancet Infect Dis. 2020"},{"key":"pone.0245024.ref054","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bcp.2017.04.009","article-title":"Repurposing bacterial toxins for intracellular delivery of therapeutic proteins","volume":"142","author":"GL Beilhartz","year":"2017","journal-title":"Biochem Pharmacol"},{"issue":"21","key":"pone.0245024.ref055","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1128\/JVI.01490-15","article-title":"Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies","volume":"89","author":"E Davidson","year":"2015","journal-title":"J Virol"},{"issue":"48","key":"pone.0245024.ref056","doi-asserted-by":"crossref","first-page":"17182","DOI":"10.1073\/pnas.1414164111","article-title":"Structures of protective antibodies reveal sites of vulnerability on Ebola virus","volume":"111","author":"CD Murin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6279","key":"pone.0245024.ref057","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"J Misasi","year":"2016","journal-title":"Science"},{"issue":"8","key":"pone.0245024.ref058","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.ajpath.2018.04.016","article-title":"Strategies to reduce the immunogenicity of recombinant immunotoxins","volume":"188","author":"R Mazor","year":"2018","journal-title":"Am J Pathol"},{"issue":"11","key":"pone.0245024.ref059","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00262-007-0321-4","article-title":"Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome","volume":"56","author":"H Wang","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"pone.0245024.ref060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-12-0336","article-title":"A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity","volume":"12","author":"JE Weldon","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"pone.0245024.ref061","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.molonc.2016.07.003","article-title":"Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy","volume":"10","author":"F Bauss","year":"2016","journal-title":"Mol Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T23:22:10Z","timestamp":1610061730000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245024"}},"subtitle":[],"editor":[{"given":"Nicholas J.","family":"Mantis","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0245024","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,1,7]]}}}